Patents by Inventor Michel P. Rathbone
Michel P. Rathbone has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10520491Abstract: Disclosed herein are cell lines transformed to express G-Protein Coupled Receptor GPCR22 and uses thereof for identifying guanosine analogues and/or other ligands to the receptor. In particular, techniques for transforming Drosophila Schneider 2 cells and human astrocytoma 1321N1 cell to express GPCR22 are disclosed as well as transformed cells lines. The transformed cell lines of the instant disclosure may be useful in identifying guanosine analogues and functional equivalents thereof.Type: GrantFiled: June 15, 2018Date of Patent: December 31, 2019Assignee: LIBRAMEN NATURALS INC.Inventors: Michel P. Rathbone, Shucui Jiang, Francesco Caciagli, Renata Ciccarelli, Patrizia Ballerini, Patrizia Di Iorio, Patricia Giuliani, Iolanda D'Alimonte
-
Publication number: 20180335422Abstract: Disclosed herein are cell lines transformed to express G-Protein Coupled Receptor GPCR22 and uses thereof for identifying guanosine analogues and/or other ligands to the receptor. In particular, techniques for transforming Drosophila Schneider 2 cells and human astrocytoma 1321N1 cell to express GPCR22 are disclosed as well as transformed cells lines. The transformed cell lines of the instant disclosure may be useful in identifying guanosine analogues and functional equivalents thereof.Type: ApplicationFiled: June 15, 2018Publication date: November 22, 2018Applicant: LIBRAMEN NATURALS INC.Inventors: Michel P. RATHBONE, Shucui JIANG, Francesco CACIAGLI, Renata CICCARELLI, Patrizia BALLERINI, Patrizia DI IORIO, Patricia GIULIANI, Iolanda D'ALIMONTE
-
Patent number: 10012641Abstract: Disclosed herein are cell lines transformed to express G-Protein Coupled Receptor GPCR22 and uses thereof for identifying guanosine analogs and/or other ligands to the receptor. In particular, techniques for transforming Drosophila Schneider 2 cells and human astrocytoma 1321N1 cell to express GPCR22 are disclosed as well as transformed cells lines. The transformed cell lines of the instant disclosure may be useful in identifying guanosine analogs and functional equivalents thereof.Type: GrantFiled: October 21, 2016Date of Patent: July 3, 2018Assignee: LIBRAMEN NATURALS INC.Inventors: Michel P. Rathbone, Shucui Jiang, Francesco Caciagli, Renata Ciccarelli, Patrizia Ballerini, Patrizia Di Iorio, Patricia Giuliani, Iolanda D'Alimonte
-
Publication number: 20170115277Abstract: Disclosed herein are cell lines transformed to express G-Protein Coupled Receptor GPCR22 and uses thereof for identifying guanosine analogues and/or other ligands to the receptor. In particular, techniques for transforming Drosophila Schneider 2 cells and human astrocytoma 1321N1 cell to express GPCR22 are disclosed as well as transformed cells lines. The transformed cell lines of the instant disclosure may be useful in identifying guanosine analogues and functional equivalents thereof.Type: ApplicationFiled: October 21, 2016Publication date: April 27, 2017Applicant: LIBRAMEN NATURALS INC.Inventors: Michel P. RATHBONE, Shucui JIANG, Francesco CACIAGLI, Renata CICCARELLI, Patrizia BALLERINI, Patrizia DI IORIO, Patricia GIULIANI, Iolanda D'ALIMONTE
-
Publication number: 20090281147Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.Type: ApplicationFiled: April 29, 2009Publication date: November 12, 2009Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Craig P. SMITH, Michel P. RATHBONE, Margaret PETTY, David RAMPE
-
Publication number: 20090270458Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.Type: ApplicationFiled: April 29, 2009Publication date: October 29, 2009Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Craig P. SMITH, Michel P. RATHBONE, Margaret PETTY, David RAMPE
-
Publication number: 20090209594Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.Type: ApplicationFiled: April 29, 2009Publication date: August 20, 2009Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Craig P. SMITH, Michel P. RATHBONE, Margaret PETTY, David RAMPE
-
Publication number: 20090209595Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.Type: ApplicationFiled: April 29, 2009Publication date: August 20, 2009Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Craig P. SMITH, Michel P. RATHBONE, Margaret PETTY, David RAMPE
-
Patent number: 7534803Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.Type: GrantFiled: September 27, 2005Date of Patent: May 19, 2009Assignee: Aventis Pharmaceuticals Inc.Inventors: Craig P. Smith, Michel P. Rathbone, Margaret Petty, David Rampe
-
Patent number: 7230015Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.Type: GrantFiled: March 14, 2005Date of Patent: June 12, 2007Assignee: Aventis Pharmaceuticals Inc.Inventors: Craig P Smith, Michel P Rathbone, Margaret Petty, David Rampe
-
Patent number: 7179821Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.Type: GrantFiled: March 14, 2005Date of Patent: February 20, 2007Assignee: Aventis Pharmaceuticals Inc.Inventors: Craig P Smith, Michel P Rathbone, Margaret Petty, David Rampe
-
Patent number: 6967210Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.Type: GrantFiled: February 14, 2002Date of Patent: November 22, 2005Assignee: Aventis Pharmaceuticals Inc.Inventors: Craig P. Smith, Michel P. Rathbone, Margaret Petty, David Rampe
-
Publication number: 20040157888Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.Type: ApplicationFiled: February 3, 2004Publication date: August 12, 2004Applicant: Aventis Pharmaceuticals Inc.Inventors: Craig P. Smith, Michel P. Rathbone, Margaret Petty, David Rampe
-
Publication number: 20040157889Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.Type: ApplicationFiled: February 3, 2004Publication date: August 12, 2004Applicant: Aventis Pharmaceuticals Inc.Inventors: Craig P. Smith, Michel P. Rathbone, Margaret Petty, David Rampe
-
Publication number: 20030105150Abstract: N-(Pyridinyl)-1H-indol-1-amines of formula I provide a unique combination of blocking properties for both the potassium and sodium channels. These compounds are useful for the treatment of Demyelinating Diseases and Conditions such as Multiple Sclerosis, Spinal Cord Injury, Traumatic Brain Injury and Stroke. The compounds are also useful for Stroke Rehabilitation, the treatment of Bladder Irritation and Dysfunction, and the treatment of Neuropathic Pain and Chemokine-Induced Pain.Type: ApplicationFiled: February 14, 2002Publication date: June 5, 2003Inventors: Craig P. Smith, Michel P. Rathbone, Margaret Petty, David Rampe
-
Publication number: 20020165242Abstract: Disclosed herein are methods and associated compositions and medicaments directed generally to the control of cellular and neural activity and for selectively and controllably inducing the in vivo genetic expression of one or more naturally occurring genetically encoded molecules in mammals. More particularly, the present invention selectively activates or derepresses genes encoding for specific naturally occurring molecules such as proteins or neurotrophic factors and induces the endogenous production of such naturally occurring compounds through the administration of carbon monoxide dependent guanylyl cyclase modulating purine derivatives. The methods of the present invention may be used to affect a variety of cellular and neurological functions and activities and to therapeutically or prophylactically treat a wide variety of neurodegenerative, neurological, cellular, and physiological disorders.Type: ApplicationFiled: February 4, 2002Publication date: November 7, 2002Inventors: Alvin J. Glasky, Michel P. Rathbone
-
Patent number: 6350752Abstract: Disclosed herein are methods and associated compositions and medicaments directed generally to the control of cellular and neural activity and for selectively and controllably inducing the in vivo genetic expression of one or more naturally occurring genetically encoded molecules in mammals. More particularly, the present invention selectively activates or derepresses genes encoding for specific naturally occurring molecules such as proteins or neurotrophic factors and induces the endogenous production of such naturally occurring compounds through the administration of carbon monoxide dependent guanylyl cyclase modulating purine derivatives. The methods of the present invention may be used to affect a variety of cellular and neurological functions and activities and to therapeutically or prophylactically treat a wide variety of neurodegenerative, neurological, cellular, and physiological disorders.Type: GrantFiled: June 19, 1997Date of Patent: February 26, 2002Inventors: Alvin J. Glasky, Michel P. Rathbone
-
Patent number: 5801184Abstract: Disclosed herein are methods directed generally to the control of neural activity and for selectively and controllably inducing the in vivo genetic expression of one or more naturally occurring genetically encoded molecules in mammals. More particularly, the present invention selectively activates or derepresses genes encoding for specific naturally occurring molecules such as neurotrophic factors through the administration of carbon monoxide dependent guanylyl cyclase modulating purine derivatives. The methods of the present invention may be used to affect a variety of cellular and neurological activities and to therapeutically or prophylactically treat a wide variety of neurodegenerative, neurological, and cellular disorders.Type: GrantFiled: June 8, 1995Date of Patent: September 1, 1998Inventors: Alvin J. Glasky, Michel P. Rathbone